Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (DGO-FMRP-USP), Ribeirão Preto, São Paulo, Brazil.
Ultrasound Med Biol. 2011 Jan;37(1):53-8. doi: 10.1016/j.ultrasmedbio.2010.10.006. Epub 2010 Nov 16.
We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol. Blood pressure and Doppler ultrasound parameters from maternal uterine and fetal middle cerebral and umbilical arteries were assessed during acute severe hypertension and after treatment. A significant reduction in systolic and diastolic blood pressure was observed in both groups. A significant change in Doppler parameters was observed only in pregnant women who received hydralazine: an increase in uterine arteries resistance index. We concluded that both drugs were highly effective in reducing blood pressure in these women. Despite the observed increase in resistance index of uterine arteries associated with hydralazine, the use of hydralazine and labetalol were not related to any significant changes in fetal Doppler, which is reassuring about the safety of these drugs when treating acute severe hypertension in pregnancy.
我们评估了 16 例妊娠 20-32 周的急性重度高血压孕妇，将其随机分为接受肼屈嗪或拉贝洛尔治疗。在急性重度高血压和治疗后评估母体子宫和胎儿大脑中动脉及脐动脉的血压和多普勒超声参数。两组孕妇的收缩压和舒张压均显著降低。仅接受肼屈嗪治疗的孕妇观察到多普勒参数的显著变化：子宫动脉阻力指数增加。我们得出结论，这两种药物均能有效降低这些孕妇的血压。尽管与肼屈嗪相关的子宫动脉阻力指数增加，但肼屈嗪和拉贝洛尔的使用与胎儿多普勒无任何显著变化相关，这对于这些药物在治疗妊娠急性重度高血压时的安全性是令人安心的。
